BioSpace News Archive

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final data collection date is six months after the last patient in. “Tumor Treating Fields therapy has demonstrated efficacy in in vitr

CIRION BioPharma Research Inc., a leading provider of large molecule bioanalytical testing and global central laboratory services, announced today that the company is now offering new testing services for the screening and clinical diagnosis of COVID–19 and expands its existing laboratory facilities by more than 7,500 sq.ft. (700 sq.m.), bri

RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies

CRH Medical Corporation, announces that it has completed an accretive transaction whereby the Company has acquired a 51% interest in Central Virginia Anesthesia Associates, LLC, a gastroenterology anesthesia practice located in Virginia.

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for Previse , the company’s algorithm designed to predict acute kidney injury (AKI) more than a full day before patients meet the clinical criteria for diagnosis. This i

LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors protect patients by testing them for COVID-19 before surgeries and other important treatments.

Reven Holdings, Inc. (“Reven”), today announced the publication of two peer-reviewed expert articles authored by its Chief Medical Officer & Chief Scientific Officer, Fatih Uckun M.D. Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).

The collaboration with Numab Therapeutics expands Boehringer Ingelheim’s bi- and multi-specific antibody pipeline with two front-runner projects in lung and gastrointestinal (GI) cancer and geographic atrophy (GA) Numab’s proprietary platform enables the engineering of first-in-class and best-in-class bi- and multi-specific antibodies in a true plug-and-play fashion

New BD PurPrep™ skin preparation is the only commercially available PVP-I antiseptic skin preparation with sterile solution in the U.S.